TOP TEN perturbations for 1553365_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553365_at
Selected probe(set): 1553365_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553365_at (1553365_at) across 6672 perturbations tested by GENEVESTIGATOR:

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.6950002
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.64889336
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):0.6344733
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

ALL study 3 (8d) / ALL study 3 (0d)

Relative Expression (log2-ratio):0.5235386
Number of Samples:2 / 2
Experimental ALL study 3 (8d)
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken 8 days after remission-induction therapy (RIT).
Control ALL study 3 (0d)
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).

PMA study 7 (12h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):0.49198532
Number of Samples:2 / 12
Experimental PMA study 7 (12h)
HepG2 cells exposed to 500nM phorbol-12-myristat-13-acetate [(PMA ortetradecanoyl phorbol acetate (TPA)] in DMSO solvent for 12 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 12 hours.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):0.48757505
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

chlorpromazine study 10 (4uM) / vehicle (DMSO) treated hepatocyte sample

Relative Expression (log2-ratio):-0.48237133
Number of Samples:2 / 2
Experimental chlorpromazine study 10 (4uM)
Hepatocytes treated with compound: chlorpromazine (4uM; CHEMBL71) for 24 hours. ATC code:
Control vehicle (DMSO) treated hepatocyte sample
Hepatocytes treated with vehicle (DMSO) for 24 hours.

multiple sclerosis study 10 (PP-MS) / cerebrospinal fluid cell sample (mixed neuropathologies)

Relative Expression (log2-ratio):-0.47990894
Number of Samples:10 / 9
Experimental multiple sclerosis study 10 (PP-MS)
Cerebrospinal fluid (CSF) cell samples from patients with primary progressive multiple sclerosis (PP-MS). Active disease was defined by the presence of any of the following criteria during 6 month prior CSF collection: (1) one or more relapses, (2) change of 0.5 point or greater in EDSS (Expanded Disability Status Score), (3) change in the number and size of lesions visualized by gadolinium-enhanced MRI. Untreated MS patients did not receive any medication for at least 1 year before CSF sample collection.
Control cerebrospinal fluid cell sample (mixed neuropathologies)
Cerebrospinal fluid (CSF) cell samples from patients with different neuropathologies, other than multiple sclerosis.

paracetamol (acetaminophen) study 11 (24h) / vehicle (PBS) treated HepG2 cell sample

Relative Expression (log2-ratio):0.4723978
Number of Samples:3 / 3
Experimental paracetamol (acetaminophen) study 11 (24h)
HepG2 cells exposed to 100μM acetaminophen (paracetamol) in PBS solvent for 24 hours. ATC code:
Control vehicle (PBS) treated HepG2 cell sample
HepG2 cells exposed to 0.5% PBS solvent for 24 hours.

ovarian tumor study 17 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):0.4703083
Number of Samples:9 / 10
Experimental ovarian tumor study 17
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.